Abstract

Because Robert Weinkam, Ph.D., has accepted an Associate Professorship at Purdue University, The Brain Tumor Research Center requests supplemental salary support to recruit a chemist to collaborate with Victor Levin, M.D., who directs the pharmacology section, and with Dennis Deen, Ph.D., who heads the biophysics section. Salary support is requested for 2 years. The chemist sought must be experienced in analytical methods of high-performance liquid chromatography, gas chromatography, and mass spectrometry. Further, the person we desire must have experience in bio-organic chemistry and be interested in making a long-term committment to anticancer drug pharmacology and developmental therapeutics. In addition to working on ongoing project proposed in CA-13525-07 dealing with PCNU pharmacokinetics and pharmacology and procarbazine pharmacokinetics and drug interactions, the to-be-named chemist would work on analytical methods and the chemistry of the development of drug resistance secondary to intracellular detoxification and transport abnormalities. All efforts would be made not to duplicate Dr. Weinkam's work in procarbazine metabolism, which he intends to do while at Purdue University.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA013525-14
Application #
3092617
Study Section
Clinical Cancer Program Project Review Committee (CCP)
Project Start
1979-04-01
Project End
1990-05-31
Budget Start
1986-07-01
Budget End
1987-05-31
Support Year
14
Fiscal Year
1986
Total Cost
Indirect Cost

  Institution

Name
University of California San Francisco
Department
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143

  Publications

Rodriguez, Fausto J; Tihan, Tarik; Lin, Doris et al. (2014) Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients. Am J Surg Pathol 38:1058-70
Chang, Susan M; Parney, Ian F; Huang, Wei et al. (2005) Patterns of care for adults with newly diagnosed malignant glioma. JAMA 293:557-64
Parney, Ian F; Kunwar, Sandeep; McDermott, Michael et al. (2005) Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 102:267-75
Prados, Michael D; Seiferheld, Wendy; Sandler, Howard M et al. (2004) Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys 58:1147-52
Levin, Victor A; Hess, Kenneth R; Choucair, Ali et al. (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9:981-90
McKnight, Tracy R; von dem Bussche, Mary H; Vigneron, Daniel B et al. (2002) Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 97:794-802
Hamel, W; Zirkel, D; Mehdorn, H M et al. (2001) (E)-5-(2-bromovinyl)-2'-deoxyuridine potentiates ganciclovir-mediated cytotoxicity on herpes simplex virus-thymidine kinase--expressing cells. Cancer Gene Ther 8:388-96
Simmons, M L; Lamborn, K R; Takahashi, M et al. (2001) Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61:1122-8
Hamel, W; Dazin, P; Israel, M A (1996) Adaptation of a simple flow cytometric assay to identify different stages during apoptosis. Cytometry 25:173-81
Hamel, W; Magnelli, L; Chiarugi, V P et al. (1996) Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 56:2697-702

Showing the most recent 10 out of 14 publications